kynurenic acid has been researched along with Lupus Erythematosus, Systemic in 3 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 8.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 4.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, EW | 3 |
| Jin, Y | 3 |
| Shih, A | 3 |
| Arazi, A | 3 |
| Goodwin, S | 3 |
| Roeser, J | 3 |
| Furie, RA | 3 |
| Aranow, C | 3 |
| Volpe, B | 3 |
| Diamond, B | 3 |
| Mackay, M | 3 |
| Xiang, ZY | 1 |
| Tang, AG | 1 |
| Ren, YP | 1 |
| Zhou, QX | 1 |
| Luo, XB | 1 |
| PINALS, RS | 1 |
3 other studies available for kynurenic acid and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Simultaneous determination of serum tryptophan metabolites in patients with systemic lupus erythematosus by high performance liquid chromatography with fluorescence detection.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Fluorescence; Humans; Kynurenic Acid; Kynurenin | 2010 |
TRYPTOPHAN METABOLISM IN RHEUMATIC DISEASE.
Topics: Amino Acids; Arthritis; Arthritis, Rheumatoid; Chromatography; Humans; Kynurenic Acid; Kynurenine; L | 1964 |